Immuno-targeting the multifunctional CD38 using nanobody
Models, Molecular
Radiology, Nuclear Medicine and Imaging
Physiology
Molecular biology
Cytotoxicity
Crystallography, X-Ray
Biochemistry
Antineoplastic Agents, Immunological
Antibody Specificity
Immunology and Microbiology
0303 health sciences
Membrane Glycoproteins
Stem cell
Life Sciences
3. Good health
Chemistry
Antigen
Medicine
Nanobodies
Epitope
Multiple Myeloma
Protein Binding
Cell biology
Therapeutic Antibodies: Development, Engineering, and Applications
Immunology
Cancer research
Article
Cell Line
03 medical and health sciences
In vitro
Cell Line, Tumor
Biochemistry, Genetics and Molecular Biology
Health Sciences
Genetics
Humans
Protein Interaction Domains and Motifs
Amino Acid Sequence
Biology
Lysosomal Calcium Signaling in Physiology and Pathology
Immunotoxin
FOS: Clinical medicine
Single-Domain Antibodies
ADP-ribosyl Cyclase 1
Immunotoxin Therapy for Cancer Treatment
FOS: Biological sciences
Protein Conformation, beta-Strand
Cell culture
CD34
Drug Screening Assays, Antitumor
CD38
DOI:
10.1038/srep27055
Publication Date:
2016-06-02T09:28:13Z
AUTHORS (15)
ABSTRACT
CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be good target for immunotherapy of the disease. CD38 also signaling enzyme responsible metabolism two novel calcium messenger molecules. To able this multifunctional protein, we generated series nanobodies against with high affinities. Crystal structures complexes were solved, identifying three separate epitopes on carboxyl domain. Chromobodies, engineered by tagging nanobody fluorescence proteins, provide fast, simple versatile tools quantifying expression. Results confirmed that was malignant MM cells compared normal white blood cells. The immunotoxin constructed splicing bacterial toxin, PE38 shows selective cytotoxicity patient-derived well lines, half maximal effective concentration reaching low 10(-11) molar. effectiveness can further increased stimulating expression using retinoid acid. These results set stage development clinical therapeutics diagnostic screening myeloma.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (56)
CITATIONS (62)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....